CURE Magazine

CURE (Cancer Updates, Research, and Education) is a complimentary magazine designed for cancer patients, survivors, and healthcare professionals working in oncology. It is the largest consumer magazine in the U.S. dedicated solely to cancer, boasting a circulation of 325,000 copies. The magazine covers a variety of subjects, including the latest cancer research, emotional and psychosocial challenges, as well as practical matters related to diagnosis and life after treatment.

National, Consumer

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#514344

United States

#183202

Health/Health Conditions and Concerns

#464

Traffic sources

Monthly visitors

Articles

Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

1 week ago | curetoday.com | Ashley Chan

Among patients with metastatic castration-sensitive prostate cancer, treatment with Erleada (apalutamide) showed consistent 24-month overall survival between real-world use and the phase 3 TITAN trial. These findings were presented at the 50th Annual Oncology Nursing Society Congress.
Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC

1 week ago | curetoday.com |

Among patients with previously treated, advanced or metastatic clear cell renal cell carcinoma (ccRCC), subcutaneous Opdivo (nivolumab and hyaluronidase-nvhy, Opdivo Qvantig) was similarly effective, safe and tolerable when compared with intravenous (IV) Opdivo, clinical trial results have shown. Updated results from the phase 3 CheckMate-67T clinical trial were presented during the 50th Annual Oncology Nursing Society Congress.
Clinical Trial of NEO100 Recruiting Patients With Malignant Gliomas

1 week ago | curetoday.com | Alex Biese

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September. Six patients are left to complete the 25-patient enrollment target of the trial, according to a news release from clinical-stage biopharmaceutical company NeOnc Technologies Holdings, Inc.
Nubeqa Combo Improves Outcomes in Metastatic Prostate Cancer

1 week ago | curetoday.com | Kristi Rosa

While the addition of Nubeqa (darolutamide) to androgen deprivation therapy proved clinically beneficial among patients with metastatic hormone-sensitive prostate cancer, the nurse’s role in educating patients on its effect and its safety is key, according to Brenda Martone, registered nurse and advanced practice provider.
Expanding Definition of Cancer Survivorship Highlights Need for New Standards

1 week ago | curetoday.com | Kristie Kahl

A survivorship program at a community health system is utilizing survivorship standards as a roadmap for collaboration across a multidisciplinary approach, as an expert illustrated.
FDA Approves Cabometyx, Another Treatment for Neuroendocrine Tumors

1 week ago | curetoday.com | Alex Biese

With the recent approval by the U.S. Food and Drug Administration (FDA) of Cabometyx (cabozantinib) for the treatment of patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET), another treatment option has become available to patients, as Dr. Jennifer Chan explained to CURE.
Trial of SVV-001, Opdivo and Yervoy in Neuroendocrine Tumors Launching

1 week ago | curetoday.com | Alex Biese

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment with a combination of immunotherapy and what has been described in a news release as a tumor-busing oncolytic virus injected directly into a tumor. The trial was announced in a news release issued by the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML

1 week ago | curetoday.com | Alex Biese

A New Drug Application (NDA) has been submitted to the Food and Drug Administration for ziftomenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM 1) mutation. The submission of the application was announced in a news release issued by Kura Oncology, Inc., and Kyowa Kirin Co., Ltd., which described the investigational drug as a highly selective, once-daily, oral, investigational menin inhibitor.
NeroSAFE May Increase Erectile Function After Prostate Cancer Surgery

1 week ago | curetoday.com | Alex Biese

Use of the NeuroSAFE technique during prostate cancer surgery nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later, researchers have found.
First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

1 week ago | curetoday.com | Alex Biese

The first patient has been dosed in a phase 1/2 clinical trial evaluating KSQ-004EX in solid tumors including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), pancreatic cancer and cervical cancer. The development was announced in a news release issued by clinical-stage biotechnology company KSQ Therapeutics, Inc.